Home » Gilead Pursues Cancer, Inflammation as Next Step to Diversify Beyond HIV
Gilead Pursues Cancer, Inflammation as Next Step to Diversify Beyond HIV
Gilead Sciences has heard it all before — it has an awesome cash machine going in the HIV drug business, but it won’t last forever, and it has never really diversified well into other disease categories.
Xconomy
Xconomy
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May